Details of the Drug

General Information of Drug (ID: DMPI98T)

Drug Name

Doxepin

Synonyms

Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin; Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin

Indication

Disease Entry	ICD 11	Status	REF
Anxiety	N.A.	Approved	[1]
Bipolar depression	N.A.	Approved	[1]
Depression	6A70-6A7Z	Approved	[2]
Insomnia	7A00-7A0Z	Approved	[1]
Pruritus	EC90	Investigative	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

279.4

Logarithm of the Partition Coefficient (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 25.5 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 12.72 mg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.25 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The clearance of drug is 0.93 L/h/kg [5]
Elimination: Less than 3% of a doxepin dose is excreted in the urine as parent compound or nordoxepin [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 15 hours [6]
Metabolism: The drug is metabolized via the transformation of N-desmethyldoxepin to its glucuronide conjugates [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 17.89643 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.2% [6]
Vd: The volume of distribution (Vd) of drug is 20 L/kg []

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Poisoning and toxicity	Not Available	CYP2D6	OTZJC802	[9]
-----------

Chemical Identifiers

Formula: C19H21NO
IUPAC Name: (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
Canonical SMILES: CN(C)CC/C=C/1\\C2=CC=CC=C2COC3=CC=CC=C31
InChI: InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+
InChIKey: ODQWQRRAPPTVAG-GZTJUZNOSA-N

Cross-matching ID

PubChem CID: 667477
CAS Number: 1668-19-5
DrugBank ID: DB01142
TTD ID: D06FES
VARIDT ID: DR00542
INTEDE ID: DR0544
ACDINA ID: D00626

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[13]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[13]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[14]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[15]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[14]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[9]
Fatty acid-binding protein, liver (FABP1)	OTR34ETM	FABPL_HUMAN	Gene/Protein Processing	[14]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Gene/Protein Processing	[16]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Gene/Protein Processing	[14]
Lanosterol synthase (LSS)	OT9W2SFH	LSS_HUMAN	Gene/Protein Processing	[14]
Lysophospholipase D GDPD3 (GDPD3)	OTOHM9QM	GDPD3_HUMAN	Gene/Protein Processing	[14]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Gene/Protein Processing	[14]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Anxiety

ICD Disease Classification

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.46E-01	-6.63E-03	-4.49E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	9.62E-01	2.57E-02	1.10E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.35E-01	2.78E-02	2.09E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Doxepin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Doxepin and Vilazodone.	Depression [6A70-6A7Z]	[17]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Doxepin and Nefazodone.	Depression [6A70-6A7Z]	[18]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Doxepin and Vortioxetine.	Depression [6A70-6A7Z]	[18]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Doxepin and Isocarboxazid.	Depression [6A70-6A7Z]	[19]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Doxepin and Milnacipran.	Depression [6A70-6A7Z]	[18]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Doxepin and Escitalopram.	Depression [6A70-6A7Z]	[20]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Doxepin and Desvenlafaxine.	Depression [6A70-6A7Z]	[18]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Doxepin and OPC-34712.	Depression [6A70-6A7Z]	[21]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Doxepin and Clomipramine.	Depression [6A70-6A7Z]	[22]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Doxepin and Esketamine.	Depression [6A70-6A7Z]	[23]
-----------


⏷ Show the Full List of 10 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Doxepin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Doxepin and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[19]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Doxepin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[24]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Midostaurin.	Acute myeloid leukaemia [2A60]	[25]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Idarubicin.	Acute myeloid leukaemia [2A60]	[25]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Arn-509.	Acute myeloid leukaemia [2A60]	[26]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[27]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Doxepin and Oliceridine.	Acute pain [MG31]	[28]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Doxepin and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[22]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Doxepin and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[22]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Doxepin and Ivabradine.	Angina pectoris [BA40]	[26]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Doxepin and Bepridil.	Angina pectoris [BA40]	[29]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Doxepin and Dronedarone.	Angina pectoris [BA40]	[25]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Doxepin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[30]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Cilostazol.	Arterial occlusive disease [BD40]	[25]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Posaconazole.	Aspergillosis [1F20]	[25]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Doxepin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[21]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Doxepin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Retigabine.	Behcet disease [4A62]	[25]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Doxepin and Cariprazine.	Bipolar disorder [6A60]	[22]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Eribulin.	Breast cancer [2C60-2C6Y]	[25]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Lapatinib.	Breast cancer [2C60-2C6Y]	[25]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Doxepin caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[33]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Bosutinib.	Breast cancer [2C60-2C6Y]	[26]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Doxepin when combined with Acetylcholine.	Cataract [9B10]	[34]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[35]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Doxepin and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[36]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Doxepin and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[36]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Doxepin and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[36]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Doxepin and Dihydrocodeine.	Chronic pain [MG30]	[28]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Doxepin and Levomilnacipran.	Chronic pain [MG30]	[18]
Mestranol	DMG3F94	Minor	Decreased metabolism of Doxepin caused by Mestranol.	Contraceptive management [QA21]	[37]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Halothane.	Corneal disease [9A76-9A78]	[25]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Sevoflurane.	Corneal disease [9A76-9A78]	[23]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Probucol.	Coronary atherosclerosis [BA80]	[25]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Doxepin and Pasireotide.	Cushing syndrome [5A70]	[25]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Osilodrostat.	Cushing syndrome [5A70]	[26]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Doxepin and Mepenzolate.	Digestive system disease [DE2Z]	[22]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Doxepin and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[17]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[25]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Deutetrabenazine.	Dystonic disorder [8A02]	[38]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Doxepin caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Doxepin and Solifenacin.	Functional bladder disorder [GC50]	[21]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Doxepin caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[40]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[25]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Doxepin and Procarbazine.	Hodgkin lymphoma [2B30]	[41]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[42]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Doxepin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Doxepin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Doxepin caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[45]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Doxepin and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[21]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Doxepin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[46]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Doxepin and ITI-007.	Insomnia [7A00-7A0Z]	[21]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Doxepin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[25]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Doxepin caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[26]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Doxepin and Crizotinib.	Lung cancer [2C25]	[47]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Doxepin and Ceritinib.	Lung cancer [2C25]	[25]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Doxepin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Doxepin caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[48]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Doxepin and Osimertinib.	Lung cancer [2C25]	[49]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Doxepin and Selpercatinib.	Lung cancer [2C25]	[50]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Doxepin and Lumefantrine.	Malaria [1F40-1F45]	[23]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Doxepin and Halofantrine.	Malaria [1F40-1F45]	[51]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Doxepin and Hydroxychloroquine.	Malaria [1F40-1F45]	[52]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[26]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Doxepin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[53]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Doxepin and Vemurafenib.	Melanoma [2C30]	[25]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and LGX818.	Melanoma [2C30]	[54]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Doxepin and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[55]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Doxepin and Flibanserin.	Mood disorder [6A60-6E23]	[56]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Doxepin and Panobinostat.	Multiple myeloma [2A83]	[57]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Doxepin and Siponimod.	Multiple sclerosis [8A40]	[23]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Doxepin and Fingolimod.	Multiple sclerosis [8A40]	[25]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Doxepin and Ozanimod.	Multiple sclerosis [8A40]	[58]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Romidepsin.	Mycosis fungoides [2B01]	[25]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Doxepin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[26]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Doxepin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[25]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[23]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Doxepin and Phenindamine.	Nasopharyngitis [CA00]	[21]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Doxepin caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[59]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Doxepin and Cyclizine.	Nausea/vomiting [MD90]	[21]
Bupropion	DM5PCS7	Major	Decreased metabolism of Doxepin caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[60]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Entrectinib.	Non-small cell lung cancer [2C25]	[26]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Doxepin and Lorcaserin.	Obesity [5B80-5B81]	[61]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Doxepin and Dexfenfluramine.	Obesity [5B80-5B81]	[18]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Doxepin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[26]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Lofexidine.	Opioid use disorder [6C43]	[26]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Rucaparib.	Ovarian cancer [2C73]	[25]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Doxepin and Oxymorphone.	Pain [MG30-MG3Z]	[28]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Doxepin and Dezocine.	Pain [MG30-MG3Z]	[28]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Doxepin and Flavoxate.	Pain [MG30-MG3Z]	[21]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Triclabendazole.	Parasitic worm infestation [1F90]	[25]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Doxepin and Safinamide.	Parkinsonism [8A00]	[58]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Doxepin and Rasagiline.	Parkinsonism [8A00]	[41]
Levodopa	DMN3E57	Minor	Altered absorption of Doxepin due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[62]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Pimavanserin.	Parkinsonism [8A00]	[63]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Doxepin and Orphenadrine.	Parkinsonism [8A00]	[22]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Doxepin and Methylscopolamine.	Peptic ulcer [DA61]	[21]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Doxepin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[24]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Doxepin and Lefamulin.	Pneumonia [CA40]	[64]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Degarelix.	Prostate cancer [2C82]	[26]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Doxepin caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[65]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Enzalutamide.	Prostate cancer [2C82]	[26]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Relugolix.	Prostate cancer [2C82]	[26]
Levomepromazine	DMIKFEL	Moderate	Increased plasma concentrations of Doxepin and Levomepromazine due to competitive inhibition of the same metabolic pathway.	Psychotic disorder [6A20-6A25]	[66]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Quetiapine.	Schizophrenia [6A20]	[25]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Doxepin and Aripiprazole.	Schizophrenia [6A20]	[21]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Doxepin and Iloperidone.	Schizophrenia [6A20]	[25]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Paliperidone.	Schizophrenia [6A20]	[25]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Doxepin and Molindone.	Schizophrenia [6A20]	[21]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Doxepin and Thiothixene.	Schizophrenia [6A20]	[21]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Doxepin and Amisulpride.	Schizophrenia [6A20]	[67]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Asenapine.	Schizophrenia [6A20]	[25]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Doxepin caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[23]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Doxepin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[25]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Doxepin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[23]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[25]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Lenvatinib.	Thyroid cancer [2D10]	[25]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Doxepin and Cabozantinib.	Thyroid cancer [2D10]	[26]
Trimeprazine	DMEMV9D	Moderate	Increased plasma concentrations of Doxepin and Trimeprazine due to competitive inhibition of the same metabolic pathway.	Vasomotor/allergic rhinitis [CA08]	[68]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Doxepin and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[21]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Doxepin caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[69]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Doxepin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[69]
-----------


⏷ Show the Full List of 125 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Diiodofluorescein	E00385	92311	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sinequan 150 mg capsule	150 mg	Oral Capsule	Oral
Sinequan 10 mg capsule	10 mg	Oral Capsule	Oral
Sinequan 100 mg capsule	100 mg	Oral Capsule	Oral
Sinequan 25 mg capsule	25 mg	Oral Capsule	Oral
Sinequan 50 mg capsule	50 mg	Oral Capsule	Oral
Sinequan 75 mg capsule	75 mg	Oral Capsule	Oral
Sinequan 6 mg tablet	6 mg	Oral Tablet	Oral
Sinequan 3 mg tablet	3 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Doxepin FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1225).
3	New zealand perfalgan report
4	BDDCS applied to over 900 drugs
5	Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Nelis HJ, De Leenheer AP: Metabolism of minocycline in humans. Drug Metab Dispos. 1982 Mar-Apr;10(2):142-6.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
11	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
12	Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4.
13	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
14	In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
15	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
16	Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain. Acta Biochim Pol. 2004;51(1):207-12.
17	Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
18	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
19	Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30. [PMID: 942286]
20	Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
21	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
22	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
23	Cerner Multum, Inc. "Australian Product Information.".
24	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
25	Canadian Pharmacists Association.
26	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
28	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
29	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
30	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
31	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
32	Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
33	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
34	Multum Information Services, Inc. Expert Review Panel.
35	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
36	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
37	Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
38	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
39	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
40	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
41	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
42	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
43	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
44	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
45	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
46	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
47	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
49	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
50	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
51	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
52	Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine). Prasco Laboratories, Cincinnati, OH.
53	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
54	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
55	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
56	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
57	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
58	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
59	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
60	James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
61	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
62	Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
63	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
64	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
65	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
66	Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
67	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
68	Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
69	Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]